spacer
 
|

Click below to register.

Saturday, September 9, 2017
Mt. Washington Conference Center

5801 Smith Avenue
Baltimore, MD
Room: 200

8:00 AM – 8:25 AM: REGISTRATION & BREAKFAST
8:25 AM – 12:20 PM: INTERACTIVE CE ACTIVITY

This activity is supported by educational grants from Alkermes, Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

OVERVIEW
Despite a number of distinct medication classes, only one-third of patients with major depressive disorder (MDD) achieve remission with initial antidepressant therapy, and a substantial number of patients fail to achieve remission after as many as 4 acute treatment trials. Furthermore, many patients who respond to antidepressant therapy may experience residual symptoms that negatively affect their quality of life and increase the likelihood of relapse. There are a number of treatment strategies for managing patients with difficult-to-treat depression, treatment-resistant depression, and residual symptoms of depression; a number of these strategies include agents of novel, unconventional mechanisms of action. This interactive regional meeting series will highlight recently approved and investigational agents for treating patients with MDD along with novel approaches to individualized therapy. Pharmacist- and nurse-driven strategies to maintain MDD treatment goals and optimize patient outcomes will be discussed through didactic presentations and break-out case-based discussions.

GOAL
The goal of this activity is to provide up-to-date comprehensive information for psychiatric pharmacist and nurse specialists on the treatment and management of patients with MDD.

INTENDED AUDIENCE
This initiative has been designed to meet the educational needs of psychiatric pharmacists, nurses, and nurse practitioners nationwide. There are no prerequisites.

LEARNING OBJECTIVES
Upon the conclusion of this activity, the participant should be able to:
  • DESCRIBE recently approved antidepressants and other novel treatments and their implications in treating MDD.
  • DISCUSS practical strategies that incorporate novel approaches to individualized MDD therapy.
  • IMPLEMENT pharmacist-driven or nursing-driven approaches to work with patients and one another to attain and maintain MDD treatment goals.
AGENDA
8:00 – 8:25 AM Registration and Breakfast
8:25 – 8:35 AM Activity Overview and Goals
8:35 – 9:30 AM Major Depressive Disorder
9:30 – 9:40 AM Question & Answer Session
9:40 – 9:55 AM Break
9:55 – 11:10 AM Break-Out Sessions
11:10 – 11:20 AM Break
11:20 AM – 12:20 PM Concluding Remarks/Question & Answer Session

This schedule is subject to change.

STEERING COMMITTEE
Patricia Cunningham, DNSc, APRN-BC
Associate Professor
Arkansas State University
Jonesboro, Arkansas
Dr Cunningham reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Patrick R. Finley PharmD, BCPP
Professor of Clinical Pharmacy
School of Pharmacy
University of California at San Francisco
San Francisco, California
Dr Finely reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

The planners and managers have nothing to disclose related to the content of this CE activity. CPNP Executive Director, Brenda Schimenti, Medical Director, Ankita Patel, PharmD, and Senior Medical Editor, Lisa Mangione, all have nothing to disclose related to the content of this CE activity.

DISCLOSURE OF UNLABELED USE AND DISCLAIMER
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information and disclosures). Dr Finley’s presentation may include discussion of off-label, experimental, and/or investigational use of drugs or devices of ketamine. The opinions expressed in the educational activity do not necessarily represent the views of CPNP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

CONTINUING EDUCATION CREDIT AND DISCLOSURES
Accreditation Statements
The College of Psychiatric and Neurologic Pharmacists (CPNP) is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

The American Psychiatric Nurses Association is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CONTINUING EDUCATION INFORMATION
Pharmacist Credit:
acpe logoThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This live activity provides 3.5 contact hours of knowledge-based credit (0.35 CEUs) from CPNP approved programming. The ACPE universal program number assigned to this course is 0284-9999-17-050-L01-P.

NABP e-PROFILE ID NUMBER: Your CE credits will be submitted electronically to the NABP. Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: https://nabp.pharmacy/cpe-monitor-service/cpe-monitor-faqs/. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. Please allow up to 30 days for your credit to appear on CPE-Monitor.

It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.

Nursing Credit:
Nurses can earn up to 3.5 continuing nursing education (CNE) contact hours for attending the live symposium and successfully completing CNE requirements. To receive full credit, you must attend the entire webcast and complete an evaluation online. The contact hours earned will be issued through an online certificate.

FAIR BALANCE AND INTEGRITY STATEMENT
It is the policy of CPNP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (eg, their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CPNP for any product or manufacturer identified.

AMERICANS WITH DISABILITIES ACT (ADA)
Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact Cathy Zehr at ASiM prior to the live event at czehr@asimcme.com (908-253-9001 ext. 15).

FEE INFORMATION
There is no fee for this educational activity.

Submit a case to review at meeting:


<img src="http://www.jhasio1.com/asim/pictures/proceed_pretestASIM.png" alt="procced to pretest" border="0" />


spacer  
  spacer
Advanced Studies in Medicine © 2014 Contact Us
spacer  
spacer